As of Nov 25
| +0.17 / +0.50%|
The 30 analysts offering 12-month price forecasts for AstraZeneca have a median target of 34.25, with a high estimate of 48.06 and a low estimate of 28.30. The median estimate represents a +0.42% increase from the last price of 34.11.
The current consensus among 31 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since November, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.